The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Aggressive Pituitary Tumors
Open accessAbstract
Pituitary adenomas are common intracranial tumors that are mainly considered as benign. Rarely, these tumors can exhibit an aggressive behavior, characterized by gross invasion of the surrounding tissues, resistance to conventional treatment leading to early and frequent recurrences. Even more rarely, pituitary tumors can give rise to cerebrospinal or systemic metastases qualifying as pituitary carcinomas according to the latest WHO definition. In the same classification, a subset of tumors with relatively distinct histopathological features was identified and defined as atypical adenomas designated to follow a more aggressive clinical course. This classification, although clinically useful, does not provide an accurate correlation between histopathological findings and the clinical behavior of these tumors, neither is it adequate to convey the precise features of ‘aggressive' tumors. Thus, ‘aggressive' pituitary adenomas need to be properly defined with clinical, radiological, histological and molecular markers in order to identify patients at increased risk of early recurrence or subsequent tumor progression. At present, no single marker or classification system of pituitary tumor aggressiveness exists, and clinically useful information in the literature is insufficient to guide diagnostic and therapeutic decisions. Treatment of patients with aggressive pituitary tumors is challenging since conventional treatments often fail, necessitating multiple surgical procedures with additional radiotherapy. Although traditional chemotherapy applied in other neuroendocrine tumors has not been shown to be efficacious, newer agents, particularly temozolomide, have shown promising results and are currently used despite the lack of data from a randomized prospective trial. Molecular targeted therapies such as mTOR and epidermal growth factor inhibitors have also been applied and might prove to be useful in the management of these patients. In the present review, we provide information regarding the epidemiology and clinical, histopathological and molecular features of aggressive pituitary tumors using recent employed definitions. In addition, we review currently employed therapeutic means providing a therapeutic algorithm and highlight the need to identify more specific disease-related and prognostic markers and the necessity for central registration of these tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Polyak, K., Lee, M.-H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., & Massagué, J. (1994) · Cell · doi:10.1016/0092-8674(94)90572-x · Cited by 2,118
Kwekkeboom, D. J., de Herder, W. W., Kam, B. L., van Eijck, C. H., van Essen, M., Kooij, P. P., Feelders, R. A., van Aken, M. O., & Krenning, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2553 · Cited by 1,456
Clinical Implications of the p53 Tumor-Suppressor Gene
Harris, C. C., & Hollstein, M. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310283291807 · Cited by 1,330
Pituitary Adenomas with Invasion of the Cavernous Sinus Space
Knosp, E., Steiner, E., Kitz, K., & Matula, C. (1993) · Neurosurgery · doi:10.1097/00006123-199310000-00008 · Cited by 1,208
Fernandez, A., Karavitaki, N., & Wass, J. A. H. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03667.x · Cited by 1,115
High Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Liège, Belgium
Daly, A. F., Rixhon, M., Adam, C., Dempegioti, A., Tichomirowa, M. A., & Beckers, A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1668 · Cited by 1,025
Transphenoidal Microsurgery of the Normal and Pathological Pituitary: Chapter X
Hardy, J. (1969) · Neurosurgery · doi:10.1093/neurosurgery/16.cn_suppl_1.185 · Cited by 640
Saeger, W., Lüdecke, D. K., Buchfelder, M., Fahlbusch, R., Quabbe, H.-J., & Petersenn, S. (2007) · European Journal of Endocrinology · doi:10.1530/eje.1.02326 · Cited by 583
Isolation and Characterization of a Pituitary Tumor-Transforming Gene (PTTG)
Pei, L. (1997) · Molecular Endocrinology · doi:10.1210/me.11.4.433 · Cited by 576
HYPOPRONOS, T. M. O., Trouillas, J., Roy, P., Sturm, N., Dantony, E., Cortet-Rudelli, C., Viennet, G., Bonneville, J.-F., Assaker, R., Auger, C., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1084-y · Cited by 545
Research works printed but not linked: 69
- 10.3171/jns.1986.64.3.0402 · doi:10.3171/jns.1986.64.3.0402
- 10.1007/s00401-005-1097-2 · doi:10.1007/s00401-005-1097-2
- 10.1530/EJE-13-1031 · doi:10.1530/eje-13-1031
- 10.1227/01.NEU.0000349930.66434.82 · doi:10.1227/01.neu.0000349930.66434.82
- 10.1227/00006123-199310000-00008 · doi:10.1227/00006123-199310000-00008 · Paper page
- 10.14310/horm.2002.1380 · doi:10.14310/horm.2002.1380
- 10.1007/s11102-008-0151-1 · doi:10.1007/s11102-008-0151-1
- 10.3171/2010.8.JNS10290 · doi:10.3171/2010.8.jns10290
- 10.5137/1019-5149.JTN.6828-12.1 · doi:10.5137/1019-5149.jtn.6828-12.1
- 10.1007/s00401-005-1093-6 · doi:10.1007/s00401-005-1093-6
- 10.1530/JME-12-0113 · doi:10.1530/jme-12-0113
- 10.1136/jcp.43.7.597 · doi:10.1136/jcp.43.7.597
- 10.1007/s00401-005-1095-4 · doi:10.1007/s00401-005-1095-4
- 10.1227/NEU.0b013e3181faa680 · doi:10.1227/neu.0b013e3181faa680
- 10.1016/j.humpath.2007.10.004 · doi:10.1016/j.humpath.2007.10.004
- 10.1210/jcem.85.10.6875 · doi:10.1210/jcem.85.10.6875
- 10.1111/j.1750-3639.2011.00476.x · doi:10.1111/j.1750-3639.2011.00476.x
- 10.1007/BF01403824 · doi:10.1007/bf01403824
- 10.1677/ERC-10-0018 · doi:10.1677/erc-10-0018
- 10.1159/000345673 · doi:10.1159/000345673
- 10.6061/clinics/2012(Sup01)09 · doi:10.6061/clinics/2012(sup01)09
- 10.1097/PAS.0b013e31815ade45 · DOI
- 10.1210/jcem.87.6.8517 · doi:10.1210/jcem.87.6.8517
- 10.1210/mend.11.4.9911 · doi:10.1210/mend.11.4.9911 · Paper page
- 10.1111/j.1365-2265.2006.02630.x · doi:10.1111/j.1365-2265.2006.02630.x
- 10.1159/000343375 · doi:10.1159/000343375
- 10.1007/s11102-012-0434-4 · doi:10.1007/s11102-012-0434-4
- 10.1210/jcem.81.2.8636285 · doi:10.1210/jcem.81.2.8636285
- 10.1210/jcem.80.3.7883846 · doi:10.1210/jcem.80.3.7883846
- 10.2152/jmi.52.151 · DOI
- 10.1007/s11102-007-0066-2 · doi:10.1007/s11102-007-0066-2
- 10.1016/j.humpath.2013.05.020 · doi:10.1016/j.humpath.2013.05.020
- 10.1023/A:1009975009924 · doi:10.1023/a:1009975009924
- 10.1677/erc.0.0090103 · doi:10.1677/erc.0.0090103
- 10.3171/jns.1986.65.6.0733 · DOI
- 10.1530/eje.0.1450137 · doi:10.1530/eje.0.1450137
- 10.1530/EJE-14-0249 · doi:10.1530/eje-14-0249
- 10.1177/147323001204000213 · doi:10.1177/147323001204000213
- 10.1111/j.1365-2265.2011.04163.x · doi:10.1111/j.1365-2265.2011.04163.x
- 10.1046/j.1365-2265.1998.00578.x · doi:10.1046/j.1365-2265.1998.00578.x
- 10.1111/j.1365-2265.1994.tb02456.x · doi:10.1111/j.1365-2265.1994.tb02456.x
- 10.1007/s11102-010-0221-z · doi:10.1007/s11102-010-0221-z
- 10.1007/s11102-008-0153-z · doi:10.1007/s11102-008-0153-z
- 10.1111/j.1365-2265.2012.04381.x · doi:10.1111/j.1365-2265.2012.04381.x
- 10.1016/j.nec.2006.04.001 · doi:10.1016/j.nec.2006.04.001
- 10.1016/j.ijrobp.2011.02.053 · doi:10.1016/j.ijrobp.2011.02.053
- 10.1227/01.NEU.0000255492.34063.32 · doi:10.1227/01.neu.0000255492.34063.32
- 10.1007/s11102-013-0541-x · doi:10.1007/s11102-013-0541-x
- 10.1530/EJE-09-0493 · doi:10.1530/eje-09-0493
- 10.1007/s11102-013-0540-y · doi:10.1007/s11102-013-0540-y
- 10.1210/jcem.83.12.5300 · doi:10.1210/jcem.83.12.5300
- 10.1111/j.1365-2265.1985.tb01076.x · doi:10.1111/j.1365-2265.1985.tb01076.x
- 10.1530/acta.0.1160347 · doi:10.1530/acta.0.1160347
- 10.1530/EJE-10-0629 · doi:10.1530/eje-10-0629
- 10.14310/horm.2002.1247 · doi:10.14310/horm.2002.1247
- 10.1007/s11060-011-0532-6 · doi:10.1007/s11060-011-0532-6
- 10.1007/s11102-009-0211-1 · doi:10.1007/s11102-009-0211-1
- 10.1055/s-0030-1253419 · doi:10.1055/s-0030-1253419
- 10.1210/jc.2009-1641 · DOI
- 10.1227/01.NEU.0000073783.96617.3A · doi:10.1227/01.neu.0000073783.96617.3a
- 10.1016/j.jocn.2009.05.013 · doi:10.1016/j.jocn.2009.05.013
- 10.1530/EJE-08-0557 · doi:10.1530/eje-08-0557
- 10.1100/tsw.2010.210 · doi:10.1100/tsw.2010.210
- 10.1227/01.NEU.0000339115.12803.4E · doi:10.1227/01.neu.0000339115.12803.4e
- 10.1155/2012/645914 · doi:10.1155/2012/645914
- 10.1007/s11102-011-0363-7 · doi:10.1007/s11102-011-0363-7
- 10.1227/NEU.0b013e318217161a · DOI
- 10.1007/s11102-010-0264-1 · doi:10.1007/s11102-010-0264-1
- 10.14310/horm.2002.1307 · doi:10.14310/horm.2002.1307
Cited by
Lee, Y. S., & Dutta, A. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092222 · Cited by 1,505
Targeting microRNAs in cancer: rationale, strategies and challenges
Garzon, R., Marcucci, G., & Croce, C. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3179 · Cited by 1,493
MicroRNA sponges: Progress and possibilities
Ebert, M. S., & Sharp, P. A. (2010) · RNA · doi:10.1261/rna.2414110 · Cited by 762
OncomiRs: the discovery and progress of microRNAs in cancers
Cho, W. C. (2007) · Molecular Cancer · doi:10.1186/1476-4598-6-60 · Cited by 719
Raverot, G., Burman, P., McCormack, A., Heaney, A., Petersenn, S., Popovic, V., Trouillas, J., Dekkers, O. M., & _, _. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0796 · Cited by 595
Pituitary Incidentaloma: An Endocrine Society Clinical Practice Guideline
Freda, P. U., Beckers, A. M., Katznelson, L., Molitch, M. E., Montori, V. M., Post, K. D., & Vance, M. L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1048 · Cited by 585
The 2017 World Health Organization classification of tumors of the pituitary gland: a summary
Lopes, M. B. S. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1769-8 · Cited by 548
The role of cellular senescence in ageing and endocrine disease
Khosla, S., Farr, J. N., Tchkonia, T., & Kirkland, J. L. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0335-y · Cited by 523
The Treatment of Cushing's Disease
Pivonello, R., De Leo, M., Cozzolino, A., & Colao, A. (2015) · Endocrine Reviews · doi:10.1210/er.2013-1048 · Cited by 465
The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy
Vogler, M., Braun, Y., Smith, V. M., Westhoff, M.-A., Pereira, R. S., Pieper, N. M., Anders, M., Callens, M., Vervliet, T., Abbas, M., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02176-0 · Cited by 462
Overview of the 2017 WHO Classification of Pituitary Tumors
Mete, O., & Lopes, M. B. (2017) · Endocrine Pathology · doi:10.1007/s12022-017-9498-z · Cited by 460
Clinical Biology of the Pituitary Adenoma
Melmed, S., Kaiser, U. B., Lopes, M. B., Bertherat, J., Syro, L. V., Raverot, G., Reincke, M., Johannsson, G., Beckers, A., Fleseriu, M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac010 · Cited by 321
Beck-Peccoz, P., Lania, A., Beckers, A., Chatterjee, K., & Wemeau, J.-L. (2013) · European Thyroid Journal · doi:10.1159/000351007 · Cited by 283
Somatostatin Analogs in Clinical Practice: A Review
Gomes-Porras, M., Cárdenas-Salas, J., & Álvarez-Escolá, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051682 · Cited by 264
Weiss, R. E., & Refetoff, S. (2000) · Reviews in Endocrine and Metabolic Disorders · doi:10.1023/a:1010072605757 · Cited by 258
TSH and thyrotropic agonists: key actors in thyroid homeostasis
Dietrich, J. W., Landgrafe, G., & Fotiadou, E. H. (2012) · Journal of Thyroid Research · doi:10.1155/2012/351864 · Cited by 146
Nishioka, H., & Yamada, S. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111951 · Cited by 65
“Since 2006, TMZ, originally approved for use for glioblastoma multiforme, has been used to successfully treat pituitary carcinomas and aggressive pituitary tumors [268] (Figure 9).”
BackgroundCytology of pituitary thyrotroph hyperplasia in protracted primary hypothyroidism
Alkhani, A. M., Cusimano, M., Kovacs, K., Bilbao, J. M., Horvath, E., & Singer, W. (1999) · Pituitary · doi:10.1023/a:1009966812195 · Cited by 38
Yedinak, C., Hameed, N., Gassner, M., Brzana, J., McCartney, S., & Fleseriu, M. (2015) · Pituitary · doi:10.1007/s11102-015-0643-8 · Cited by 27
Ghannam, N. N., Hammami, M. M., Muttair, Z., & Bakheet, S. M. (1999) · Journal of Endocrinological Investigation · doi:10.1007/bf03343584 · Cited by 25
Roux, A., Rosso, D., Cuboni, D., Maccario, M., Grottoli, S., Arvat, E., & Gasco, V. (2024) · Biomedicines · doi:10.3390/biomedicines12061368 · Cited by 9
Ren, X., Wang, X., Chen, G., Liu, X., Guo, H., & Li, M. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01357-8 · Cited by 5
Metadata
- Authors
- Chatzellis, E., Alexandraki, K. I., Androulakis, I. I., & Kaltsas, G.
- Venue
- Neuroendocrinology
- Publisher
- S. Karger AG
- Published
- 2015
- Volume
- 101
- Issue
- 2
- Pages
- 87-104
- ISSN
- 0028-3835 (ISSN-L)
- 1423-0194
- OpenAlex
- W1607070363
- Cited by
- 572
- References
- 77
- FWCI
- 45.31
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.